- Design
- Systematic review and meta-analysis of mixed study types
- Population
- Patients receiving semaglutide in trials, cohorts and pharmacovigilance data
- Primary outcome
- Risk of depression
- Effect
- RR 1.25 (95% CI 0.95–1.65), I² 98%
A systematic review and meta-analysis in Clinical Obesity pooled randomised trials, observational studies, database analyses and pharmacovigilance disproportionality studies of semaglutide, searched to January 2026.
The pooled risk ratio for depression was 1.25 (95% CI 0.95–1.65), for anxiety 1.22 (0.93–1.60), and for suicidal ideation or attempt 1.20 (0.90–1.62). None was statistically significant. Heterogeneity was extreme (I² 92–99%), reflecting the mix of very different data sources, including spontaneous reports that are prone to reporting bias.
The authors frame the result as absence of a detected risk rather than proof of safety. Mechanistically, there is no established pathway, and the large outcome trials have not shown a psychiatric signal. For prescribers this supports continuing semaglutide while keeping mood on the follow-up checklist, especially in people with prior depression.
- No significant increase in depression, anxiety or suicidal ideation was found with semaglutide.
- Ask about mood at follow-up, particularly in patients with a history of depression.
- Advise patients to report new low mood or suicidal thoughts promptly.
- Point estimates above 1.0 with wide intervals mean a small risk has not been excluded.
Why it matters
Regulators have looked at this question and patients ask about it; this is the current state of the evidence.
Don't overread it
Absence of a significant signal in highly heterogeneous data is not proof that semaglutide carries no psychiatric risk.
The statistics, in plain English
A risk ratio of 1.25 with an interval from 0.95 to 1.65 is compatible with no effect or a moderate increase. I² near 99% means the studies disagreed so much that a single pooled number is of limited meaning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free